Author Archives: Ana Pena, PhD

Vertex Partners with Ribometrix to Discover RNA-targeted Therapies

Vertex Pharmaceuticals has entered a strategic collaboration with Ribometrix to discover potential RNA-targeted therapies for serious diseases. Vertex is a leader in the market of CFTR modulators for cystic fibrosis (CF), and is the developer of Kalydeco (ivacaftor), Orkambi (ivacaftor/lumacaftor), and Symdeko (tezacaftor/ivacaftor combination therapy), three approved CF…

Pancreas-on-a-chip Expected to Shed Light, Help Find New Treatments for CF-related Diabetes

Scientists have created a miniature human pancreas-on-a-chip that may help identify the cause of cystic fibrosis-related diabetes (CFRD), a common and life-threatening complication of cystic fibrosis (CF). Researchers believe the pancreas-on-a-chip will provide insightful information about the biology of CFRD, offering a reliable way to monitor pancreatic cell responses and…

Phage Therapy May Help Resolve Multidrug-resistant Pseudomonas Airway Infections, Case Report Suggests

Armata Pharmaceuticals‘ investigational phage therapy AP-PA01 combined with antibiotics holds promise for treating multidrug-resistant Pseudomonas airway infections, updated data from a case study show. A young woman with cystic fibrosis (CF) was successfully treated for a multidrug-resistant Pseudomonas aeruginosa pneumonia using AP-PA01 and antibiotics. At 100 days…


Featured Column

What It’s Like to Have a Family Member in the ICU

Main graphic for "Safe and Sound," Cystic Fibrosis News Today, by columnist Shelby Dell
Five years after her brother, Bradley, fought for his life in the ICU, columnist Shelby Dell reflects on how his hospitalization affected her.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.